STOCK TITAN

Capital Research reports 6% IDEAYA Biosciences (IDYA) ownership stake

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

IDEAYA Biosciences, Inc. received an updated ownership report from Capital Research Global Investors, which reports beneficial ownership of 5,279,675 shares of IDEAYA common stock. This represents 6.0% of the 87,666,408 shares believed to be outstanding as of the reported date.

Capital Research Global Investors has sole power to vote and dispose of all 5,279,675 shares and no shared voting or dispositive power. The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of IDEAYA.

Positive

  • None.

Negative

  • None.

Insights

Capital Research reports a 6% passive stake in IDEAYA.

Capital Research Global Investors reports beneficial ownership of 5,279,675 IDEAYA Biosciences shares, equal to 6.0% of 87,666,408 shares believed outstanding. The firm holds sole voting and dispositive power over these shares, indicating a concentrated institutional position.

The certification specifies that the position is held in the ordinary course of business and not to change or influence control. That language aligns with a passive institutional investment under Schedule 13G, rather than an activist stance.

As a result, this disclosure mainly informs the market about the presence and size of a significant institutional holder. Any future changes in this stake would be reflected in subsequent beneficial ownership filings if they cross regulatory thresholds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many IDEAYA (IDYA) shares does Capital Research Global Investors own?

Capital Research Global Investors reports beneficial ownership of 5,279,675 IDEAYA Biosciences common shares. This stake reflects shares over which it has sole voting and dispositive power, as disclosed in the Schedule 13G/A ownership section.

What percentage of IDEAYA (IDYA) does Capital Research Global Investors hold?

Capital Research Global Investors holds 6.0% of IDEAYA Biosciences’ common stock. This percentage is based on 5,279,675 shares compared with 87,666,408 shares believed to be outstanding, as stated in the ownership disclosure.

Is Capital Research Global Investors an active or passive investor in IDEAYA (IDYA)?

The filing characterizes Capital Research Global Investors as a passive investor. It certifies the IDEAYA shares were acquired and are held in the ordinary course of business, not for changing or influencing control of the company.

Does Capital Research Global Investors share voting power over IDEAYA (IDYA) shares?

No. The filing states Capital Research Global Investors has sole voting power over 5,279,675 IDEAYA shares and shared voting power over zero shares. It also has sole, and no shared, dispositive power over the same amount.

What is the date of the ownership event reported for IDEAYA (IDYA)?

The ownership information relates to an event dated 12/31/2025. That date is identified as the event requiring the filing of the Schedule 13G/A, which reports Capital Research Global Investors’ 6.0% beneficial ownership position.

Who signed the IDEAYA (IDYA) Schedule 13G/A for Capital Research?

The Schedule 13G/A was signed by Jae Won Chung, identified as Vice President and Senior Counsel II of Capital Research and Management Company. The signature is dated 02/05/2026, certifying the accuracy of the ownership disclosure.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Capital Research Global Investors
Signature:Jae Won Chung
Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
Date:02/05/2026